The listings on this site are from companies that may compensate us. This influences where, how, and in what order such listings appear. Advertising Disclosure

Tirzepatide Articles & Guides

In-depth editorial guides on tirzepatide for weight loss — mechanism, outcomes, side effects, dosing, and provider comparisons.

Comparisons 9 min read

Tirzepatide vs Semaglutide

Side-by-side comparison of tirzepatide and semaglutide for weight loss in 2026. Mechanism, efficacy, cost, side effects, and which is right for you.

Read article →
Science & Mechanism 8 min read

How Tirzepatide Works

How tirzepatide produces weight loss through dual GLP-1 and GIP receptor activation. Mechanism, biology, and what makes it different from other GLP-1 medications.

Read article →
Outcomes & Expectations 7 min read

Expected Weight Loss on Tirzepatide

What weight loss to realistically expect on tirzepatide. SURMOUNT-1 trial results by dose, weekly weight loss patterns, and how to maximize results.

Read article →
Practical Guides 8 min read

How to Take Tirzepatide

Complete guide to taking tirzepatide injections in 2026. Dosing schedule, injection technique, missed-dose handling, and storage.

Read article →
Safety & Side Effects 9 min read

Tirzepatide Side Effects

Complete guide to tirzepatide side effects. Common GI effects, serious risks, FDA boxed warning, and how to manage adverse events through dose titration.

Read article →

Frequently Asked Questions

How often are GLP1OneTelehealth articles updated?
Articles are reviewed on rolling cycles: practical guides and provider-related content every 60 days; clinical mechanism and trial content every 90 days; cost and regulatory content every 30-45 days. Last full editorial review: May 15, 2026.
Who writes these articles?
Articles are written by the GLP1OneTelehealth Editorial Team and reviewed for clinical accuracy against FDA prescribing information and peer-reviewed trial reports. Content is informational, not medical advice.
Can I cite these articles in academic or clinical work?
GLP1OneTelehealth articles are editorial in nature and not peer-reviewed clinical literature. For academic citations, please reference the primary sources we cite (FDA labels, published trials in NEJM, Lancet, JAMA, etc.) rather than this site directly.